Cancer treatment and research communications最新文献

{"title":"Clinical and pathological differences between early- and late-onset colorectal cancer and determinants of one-year all-cause mortality among advanced-stage patients: a retrospective cohort study in Medellín, Colombia","authors":"Álvaro Esteban Ruiz Grajales ,&nbsp;Manuela María Orozco Puerta ,&nbsp;Senshuang Zheng ,&nbsp;Geertruida H. de Bock ,&nbsp;Juan Camilo Correa Cote ,&nbsp;Esteban Castrillón Martínez","doi":"10.1016/j.ctarc.2024.100797","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100797","url":null,"abstract":"<div><h3>Objective</h3><p>To identify the differences between early- (EOCRC) and late-onset colorectal cancer (LOCRC), and to evaluate the determinants of one-year all-cause mortality among advanced-stage patients.</p></div><div><h3>Methods</h3><p>A retrospective cohort study was carried out. CRC patients ≥ 18 years old were included. Chi-Square test was applied to compare both groups. Uni- and multivariate regressions were performed to evaluate the determinants of one-year all-cause mortality in all advanced-stage patients regardless of age of onset.</p></div><div><h3>Results</h3><p>A total of 416 patients were enrolled; 53.1 % were female. Ninety cases (21.6 %) had EOCRC and 326 (78.4 %) had LOCRC. EOCRC cases were predominantly sporadic (88.9 %). Histology of carcinoma other than adenocarcinoma (<em>p</em> <em>=</em> 0.044) and rectum tumors (<em>p</em> <em>=</em> 0.039) were more prevalent in EOCRC. LOCRC patients were more likely to have smoking history <em>(p</em> &lt; 0.001) and right colon tumors (<em>p</em> = 0.039). Alcohol consumption history (odds ratio [OR]: 3.375, 95 %CI: 1.022–11.150) and stage IV (OR: 12.632, 95 %CI: 3.506–45.513) were associated with higher one-year all-cause mortality among advanced-stage patients, the opposite was noted with left colon tumors (OR: 0.045, 95 %CI: 0.003–0.588).</p></div><div><h3>Conclusion</h3><p>EOCRC was predominantly sporadic and had more cases of uncommon histological subtypes and rectal tumors. LOCRC was characterized by a higher prevalence of smoking history. Multivariate regression revealed an association between higher one-year all-cause mortality and alcohol consumption history and stage IV in advanced-stage patients. CRC exhibited differences based on age of onset. The evaluated factors associated with CRC mortality provide valuable insights for healthcare professionals, emphasizing the importance of adequate clinical assessment and early CRC diagnosis.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000091/pdfft?md5=6da1553e1727aa40e30c374c36841037&pid=1-s2.0-S2468294224000091-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139744024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liposomes for the treatment of prostate cancer therapy: A review","authors":"Chinmaya Keshari Sahoo ,&nbsp;Nalini Kanta Sahoo ,&nbsp;Madhusmita Sahu","doi":"10.1016/j.ctarc.2024.100792","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100792","url":null,"abstract":"<div><p>One of the cancers that affect men, prostate cancer considerably raises mortality rates for males around the world. Patients with prostate cancer can have a localized or advanced form of the illness. Digital rectal examinations, prostate-specific antigen analyses, and prostate biopsies are all used to identify prostate cancer. The onset, development, and spread of cancer are all correlated with mutations in specific genes. Radical prostatectomy, ablative radiation, and active surveillance are all forms of treatment for localized prostate cancer. Androgen deprivation therapy (ADT), radiation, and chemotherapy are given to men who have metastatic prostate cancer or have experienced a relapse. When compared to traditional cancer chemotherapeutic methods, the liposome-based drug delivery technology offers less toxic, biodegradable, and biocompatible nanomedicine. Liposomes offer great advantages for use in nanomedicines by improving the sensitivity, specificity, and persistence of these anti-malignant cell agents in the body. Liposomal formulations are undergoing clinical trials of variety of cancers including prostate cancer. The present narrative review describes the composition and types of liposomes, its advantages, disadvantages, and the methods of preparation, research studies, clinical applications, drug repurposing and administration.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000042/pdfft?md5=d1106ca49593ac606acb12a54a6fa284&pid=1-s2.0-S2468294224000042-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139744463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor circulating biomarkers in colorectal cancer","authors":"Raana Bagheri ,&nbsp;Mohsen Ghorbian ,&nbsp;Saeid Ghorbian","doi":"10.1016/j.ctarc.2023.100787","DOIUrl":"10.1016/j.ctarc.2023.100787","url":null,"abstract":"<div><p>CRC is a major global health concern and is responsible for a significant number of cancer-related deaths each year. The successful treatment of CRC becomes more difficult when it goes undetected until it has advanced to a later stage. Diagnostic biomarkers can play a critical role in the early detection of CRC, which leads to improved patient outcomes and increased survival rates. It is important to develop reliable biomarkers for the early detection of CRC to enable timely diagnosis and treatment. To date, CRC detection methods such as endoscopy, blood, and stool tests are imperfect and often only identify cases in the later stages of the disease. To overcome these limitations, researchers are turning to molecular biomarkers as a promising avenue for improving CRC detection. Diagnostic information can be provided more reliably through a noninvasive approach using biomarkers such as mRNA, circulating cell-free DNA, micro-RNA, long non-coding RNA, and proteins. These biomarkers can be found in blood, tissue, feces, and volatile organic compounds. The identification of molecular biomarkers with high sensitivity and specificity for early detection of CRC that are safe, cost-effective, and easily measurable remains a significant challenge for researchers. In this article, we will explore the latest advancements in blood-based diagnostic biomarkers for CRC and their potential impact on improving patient survival rates.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294223001090/pdfft?md5=62ecd886748f2708c202c98f6ed2deed&pid=1-s2.0-S2468294223001090-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139019700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of cervical cancer screening and determinant factors among female nurses in selected public hospitals in Addis Ababa, Ethiopia","authors":"Winta Tesfaye ,&nbsp;Bezawit Ashine ,&nbsp;Yadelew Yimer ,&nbsp;Yibeltal Yismaw ,&nbsp;Gedamnesh Bitew ,&nbsp;Tseganesh Asefa ,&nbsp;Kirubel Girmay ,&nbsp;Habtu Kifle Negash ,&nbsp;Yitbarek Fantahun Marye ,&nbsp;Hiwot Tezera","doi":"10.1016/j.ctarc.2024.100815","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100815","url":null,"abstract":"<div><h3>Background</h3><p>Cervical cancer is one of the top cause of death among childbearing women globally and public health issue for underdeveloped nations.It is the world's second most prevalent cancer among women. In 2018, 311,000 women died due to cervical cancer.Approximately 80 % of these deaths occurred in developing countries.However, there has been insufficient research on cervical cancer screening utilisation among Ethiopian nurses, despite the fact that nurses promote women's health and play a key role in cervical cancer education. As a result, evaluating utilization of cervical cancer screening among nurses is critical for program effectiveness.</p></div><div><h3>Objective</h3><p>To assess the magnitude of utilization of cervical cancer screening and determinant factors among female Nurses in selected public hospitals in Addis Ababa, Ethiopia.</p></div><div><h3>Methodology</h3><p>An institutional-based cross-sectional study design was employed from October 1 to November 30, 2022. Data was collected using an interviewer-administered questionnaire. The data was entered into Epi data version 3.1 and then exported to SPSS version 22 for data management and analysis. Bivariate and multi-variable logistic regressions were employed to identify the predictor variables. Statistical significance was considered at <em>P</em> &lt; 0.05 with adjusted odds ratio calculated at 95 % CI.</p></div><div><h3>Result</h3><p>The magnitude of utilization of cervical cancer screening among nurses working in selected public hospitals in Addis Ababa was 18.5 % (95 % CI: 14.2, 23.1). Having work experience &gt; 8 years (AOR = 16.78; 95 % CI: 4.82, 58.44), history of STI (AOR = 53.72; 95 % CI: 14.18, 203.45) and having multiple sexual partners (AOR = 12.74; 95 % CI: 4.15, 39.11) were significantly associated with utilization of cervical cancer screening among female nurses.</p></div><div><h3>Conclusion</h3><p>The overall cervical cancer screening rate among female nurses was low compared to the WHO strategy for cervical cancer elimination, which asks for 70 % of women worldwide to be checked for cervical illnesses regularly by 2030. According to the study findings, respondents' work experience, STI history, and having multiple sexual partners influenced their utilization of cervical cancer screening among nurses. To boost the utilization of screening services, female nurses should place a strong emphasis on maintaining screening awareness through education and knowledge sharing.Finally, we recommend future researchers to do comparative study design to draw any scientific and credible conclusions.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000273/pdfft?md5=4bbc3cd85d88c499dfcf879c076d155d&pid=1-s2.0-S2468294224000273-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140906753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified swede colposcopic index versus modified reid index in colposcopic screening for premalignant & malignant lesions of the cervix: a cross-sectional analysis","authors":"Dr. Swati Priya ,&nbsp;Dr. Amiy Arnav ,&nbsp;Dr. Swati Mittal ,&nbsp;Dr. Pammy Pravina ,&nbsp;Dr Suhagini Murmu ,&nbsp;Dr. Gauri Gandhi","doi":"10.1016/j.ctarc.2024.100828","DOIUrl":"10.1016/j.ctarc.2024.100828","url":null,"abstract":"<div><h3>Background</h3><p>Cervical cancer cases in India account for one-fourth of the worldwide burden. Colposcopy is used to evaluate the cervix of women with abnormal screening test results. For standardized reporting, various scores were introduced of those, Reid Colposcopic Index (RCI) and Swede score are the most commonly used.</p></div><div><h3>Aims and Objectives</h3><p>This study is undertaken to determine the diagnostic efficacy and clinical relevance of the newly introduced MSCI and compare MSCI and Modified Reid Index.</p></div><div><h3>Results</h3><p>225 women out of 237 were analyzed. MSCI score 9 perform best for colposcopic diagnosis of CIN 2 or higher lesions. The sensitivity, specificity, PPV, and NPV for threshold score 9 for CIN 2 or higher lesions were 94.92 %, 67.88 %, 51.38 %, and 97.39 % respectively. Modified Reid Index threshold 3 performed best for the detection of CIN 2 or higher lesions with a sensitivity, specificity, PPV, and NPV of 84.75 %, 44.85 %, 35.46 %, and 89.16 % respectively. On comparing the area under the curve (AUC) for MSCI and MRI, we found that the difference between the AUC of MSCI (0.854) and Modified Reid Index (0.657) was significant (<em>P</em> &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>MSCI performs better than the modified reid index for the diagnosis of both HGL and LGL or higher. Also, the omission of impractical measurements and inclusion of easier and more practical parameters than the Swede score or Modified Reid Index makes MSCI a simple and effective screening tool</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000406/pdfft?md5=33a00a46c074cd4566c485da1a2b3bd9&pid=1-s2.0-S2468294224000406-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparison","authors":"João Coutinho-Almeida ,&nbsp;Ana Sofia Silva ,&nbsp;Patrícia Redondo ,&nbsp;Pedro Pereira Rodrigues ,&nbsp;Ana Ferreira","doi":"10.1016/j.ctarc.2024.100818","DOIUrl":"10.1016/j.ctarc.2024.100818","url":null,"abstract":"<div><h3>Introduction/Background</h3><p>Hormone Receptor-positive (HR+) and Human Epidermal Growth Factor Receptor 2-negative (HER2-) breast cancer is the most common subtype, predominantly treated with endocrine therapy. The efficacy of CDK4/6 inhibitors combined with endocrine therapy in this context remains to be fully evaluated.</p></div><div><h3>Materials (or Patients) and Methods</h3><p>This study compared the effectiveness of CDK4/6 inhibitors (palbociclib and ribociclib) in combination with an aromatase inhibitor or fulvestrant against endocrine therapy alone in patients with HR+/HER2- advanced breast cancer. The main focus was on progression-free survival (PFS) and overall survival (OS). The study involved a population treated exclusively with endocrine therapy for bone involvement, examining median OS and PFS, and adjusting for variables like stage, visceral metastasis, age, and treatment line.</p></div><div><h3>Results</h3><p>The study found no significant OS difference between treatments with palbociclib, ribociclib, and endocrine therapy alone. However, ribociclib combined with letrozole significantly improved PFS over letrozole alone. Propensity score weighting indicated a potential 50 % reduction in death risk with ribociclib compared to palbociclib, though this was not confirmed by cox regression.</p></div><div><h3>Conclusion</h3><p>CDK4/6 inhibitors, particularly ribociclib in combination with letrozole, show promise in improving outcomes for HR+/HER2- breast cancer patients. While palbociclib may not be superior to traditional endocrine therapy, the results underscore the need for further research. These findings could influence future treatment protocols, emphasizing the importance of personalized therapy in this patient group.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000303/pdfft?md5=c85a200ed6dc7db0d9407ce41bbdc77d&pid=1-s2.0-S2468294224000303-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early onset metastatic colorectal cancer in Australia","authors":"A. Jalali ,&nbsp;S. Smith ,&nbsp;G. Kim ,&nbsp;H. Wong ,&nbsp;M. Lee ,&nbsp;J. Yeung ,&nbsp;M. Loft ,&nbsp;R. Wong ,&nbsp;J.D. Shapiro ,&nbsp;S. Kosmider ,&nbsp;J. Tie ,&nbsp;S. Ananda ,&nbsp;B. Ma ,&nbsp;M. Burge ,&nbsp;R. Jennens ,&nbsp;B. Lee ,&nbsp;J. Johns ,&nbsp;L. Lim ,&nbsp;A. Dean ,&nbsp;L. Nott ,&nbsp;P. Gibbs","doi":"10.1016/j.ctarc.2024.100827","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100827","url":null,"abstract":"<div><h3>Background</h3><p>Colorectal cancer (CRC) incidence and mortality rates have been increasing among young patients (YP), for uncertain reasons. It is unclear whether YP have a distinct tumor biology or merit a different treatment approach to older patients (OP).</p></div><div><h3>Methods</h3><p>We reviewed prospectively collected data from consecutive patients with metastatic CRC (MCRC) enrolled in the multi-site Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) Australian registry. Clinicopathological features, treatment and survival outcomes were compared between YP (&lt;50 years) and OP (≥50 years).</p></div><div><h3>Results</h3><p>Of 3692 patients diagnosed August 2009 - March 2023, 14 % (513) were YP. YP were more likely than OP to be female (52% vs. 40 %, <em>P</em> &lt; 0.0001), have ECOG performance status 0–1 (94% vs. 81 %, <em>P</em> &lt; 0.0001), to have a left-sided primary (72% vs. 63 %, <em>P</em> = 0.0008) and to have fewer comorbidities (90% vs. 60 % Charleston score 0, <em>P</em> &lt; 0.0001). There were no differences in the available molecular status, which was more complete in YP. YP were more likely to have de novo metastatic disease (71% vs. 57 %, <em>P</em> &lt; 0.0001). YP were more likely to undergo curative hepatic resection (27% vs. 17 %, <em>P</em> &lt; 0.0001), to receive any chemotherapy (93% vs. 78 % (<em>P</em> &lt; 0.0001), and to receive 3+ lines of chemotherapy (30% vs. 24 % (<em>P</em> &lt; 0.0034)). Median first-line progression free survival (10.2 versus 10.6 months) was similar for YP vs OP, but overall survival (32.1 versus 25.4 months, HR = 0.745, <em>P</em> &lt; 0.0001) was longer in YP.</p></div><div><h3>Conclusion</h3><p>Known prognostic variables mostly favored YP versus OP with newly diagnosed mCRC, who were also more heavily treated. Consistent with this, overall survival outcomes were improved. This data does not support that CRC in YP represent a distinct subset of mCRC patients, or that a modified treatment approach is warranted.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S246829422400039X/pdfft?md5=ae7bbb9db3be665da9f27da6302a81ed&pid=1-s2.0-S246829422400039X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141333064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invited commentary on “The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: A retrospective study”","authors":"","doi":"10.1016/j.ctarc.2024.100806","DOIUrl":"10.1016/j.ctarc.2024.100806","url":null,"abstract":"<div><p>The article “The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: A retrospective study” have presented the experience of AVD chemotherapy regimen in newly diagnosed Hodgkin's lymphoma (HL) in a single center in Brazil. Though being a small retrospective study, results from this study have provided the medical community a real-world data on HL in Brazil. ABVD has remained the standard of care for patients of newly diagnosed HL both in early and advance stages. Newer targeted molecules have also come for use in novel combinations with existing drugs. However, in a situation of temporary scarcity of bleomycin due to lack of supply during 2017 in Brazil led to use of incomplete ABVD regimen without bleomycin, i.e. AVD for HL. However, Soldi et al. utilized the opportunity to retrospectively study if the omission of bleomycin leads to subnormal treatment or unwarranted effects.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000182/pdfft?md5=cdb30affa96b38910d56529090f337a3&pid=1-s2.0-S2468294224000182-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140136503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcopenia in gastric cancer and its impact on early postoperative outcome","authors":"","doi":"10.1016/j.ctarc.2024.100829","DOIUrl":"10.1016/j.ctarc.2024.100829","url":null,"abstract":"<div><h3>Background</h3><p>Sarcopenia, defined as progressive and generalised loss of skeletal muscle mass, quality, and strength, is considered as a poor prognostic factor in cancer. Outcomes in oncology mainly focus on survival related to disease and treatment. Other factors affecting the end result get less attention. This study was conducted with the aim to determine presence of sarcopenia in operable gastric cancer, factors positively correlating with presence of sarcopenia and its impact on early postoperative outcomes.</p></div><div><h3>Methodology</h3><p>This is a prospective study conducted from January 2020 to December 2021 in a tertiary care cancer hospital. All patients with adenocarcinoma stomach planned for curative intent surgery were assessed for sarcopenia by measuring hand grip strength(HGS) and skeletal muscle index(SMI). Comparison was made between patient and tumour related factors in patients with and without sarcopenia and impact of sarcopenia on early postoperative outcome was assessed.</p></div><div><h3>Results</h3><p>74 patients were assessed for sarcopenia. 32 (43.2 %) were patients diagnosed with sarcopenia. Advanced age(<em>p</em> = 0.040), low BMI (<em>p</em> &lt; 0.001), gastric outlet obstruction (<em>p</em> = 0.020) and urgent surgery (<em>p</em> = 0.002) positively correlated with sarcopenia. Curative resection was done in 68(91.89 %) patients and these patients were evaluated for early postoperative outcomes. 18 (26.5 %) patients had complications of Clavien Dindo grade 3 or above. Sarcopenia was not significantly associated with major postoperative complications(<em>p</em> = 0.857).</p></div><div><h3>Conclusion</h3><p>Sarcopenia, though associated with a substantial proportion of patients with gastric cancer, does not significantly affect early postoperative complications in a high volume oncology centre .</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000418/pdfft?md5=2072b55a4a18ef912b997cd606da6570&pid=1-s2.0-S2468294224000418-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy-related breast cancer: 14-year experience in a tertiary institution in Hong Kong","authors":"Billy Ho Hung Cheung ,&nbsp;Vivian Chi Mei Man ,&nbsp;Goby Tze Wa Sham ,&nbsp;Lorraine Chow ,&nbsp;Michael Co ,&nbsp;Ava Kwong","doi":"10.1016/j.ctarc.2023.100783","DOIUrl":"10.1016/j.ctarc.2023.100783","url":null,"abstract":"<div><h3>Background</h3><p>The incidence of pregnancy-associated breast cancer (PABC) is increasing. Its tumor characteristics and overall survival compared with those in nonpregnant patients remain controversial. While there have been suggestions that PABC patients have a 40 % increase in the risk of death compared to non-pregnant patients, other studies suggested similar disease outcomes. This study aims to review our local experience with PABC.</p></div><div><h3>Methods</h3><p>Twenty-eight patients diagnosed with PABC and twenty-eight patients diagnosed at premenopausal age randomly selected by a computer-generated system during the same period were recruited. Background characteristics, tumor features, and survival were compared.</p></div><div><h3>Results</h3><p>Among the twenty-eight pregnant patients, seventeen were diagnosed during pregnancy, and eleven were diagnosed in the postpartum period. Compared to the non-pregnant breast cancer patients, they presented with less progesterone receptor-positive tumor (35.7 % vs. 64.2 %, <em>p</em> = 0.03). Although there was no statistically significant difference in tumor size (<em>p</em> = 0.44) and nodal status (<em>p</em> = 0.16), the tumor tended to be larger in size (2.94 +/− 1.82 vs 2.40 +/− 1.69 cm) and with more nodal involvement (35.7 % vs 25.0 %). There was also a trend of delayed presentation to medical attention, with a mean duration of 13.1 weeks in the PABC group and 8.6 weeks in the control group. However, the overall survival did not differ (<em>p</em> = 0.63).</p></div><div><h3>Conclusion</h3><p>PABC is increasing in incidence. They tend to have more aggressive features, but overall survival remains similar. A multidisciplinary approach is beneficial for providing the most appropriate care.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294223001053/pdfft?md5=7e4fd94c0127cf4bcd40a195119bd949&pid=1-s2.0-S2468294223001053-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138992672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}